A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2006
12/14/2006	WO2006132442A1 Vitamin d-like compound
12/14/2006	WO2006132438A1 1,3-benzothiazinone derivative and use thereof
12/14/2006	WO2006132430A1 Process for production of polymerized coordination compound of platinum complex
12/14/2006	WO2006132401A1 Method for evaluation of compound using rsk1
12/14/2006	WO2006132388A1 Bone marrow-directing drug delivery materials and their applications
12/14/2006	WO2006132251A1 Prophylactic/therapeutic agent for adult t cell leukemia
12/14/2006	WO2006132248A1 Method for ubiquitination of runx
12/14/2006	WO2006132245A1 Tumor growth inhibitor
12/14/2006	WO2006132204A1 Transcription factor decoy
12/14/2006	WO2006131923A2 Novel salts of conjugated psychotropic drugs and processes of preparing same
12/14/2006	WO2006131649A2 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
12/14/2006	WO2006131515A2 Stabilised il-21 compositions
12/14/2006	WO2006131496A2 Hdac regulation assays, compounds and therapeutic compositions
12/14/2006	WO2006131484A1 Indole derivatives having antitumor activity
12/14/2006	WO2006131482A1 Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumour agents
12/14/2006	WO2006131394A1 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
12/14/2006	WO2006131393A1 Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
12/14/2006	WO2006131186A1 Oxindoles as kinase inhibitors
12/14/2006	WO2006131003A1 Angiogenesis inhibitors
12/14/2006	WO2006130994A1 Synthesis of glycerolipid carbamates and dicarbamates and their use as antitumor compounds
12/14/2006	WO2006130943A1 Respirable dried powder formulation comprising drug loaded nanoparticles
12/14/2006	WO2006116733A3 Protein kinase inhibitors
12/14/2006	WO2006099175A3 Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
12/14/2006	WO2006095139A3 Cancer treatment using specific 3,6,9-substituted acridines
12/14/2006	WO2006094917A3 Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors
12/14/2006	WO2006089177A3 Isoxazole combretastin derivatives for the treatment of disorders
12/14/2006	WO2006084017A3 Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
12/14/2006	WO2006078274A3 Beta-peptides
12/14/2006	WO2006075095A3 Use of purine derivatives as hsp90 protein inhibitors and for treatment of cancer
12/14/2006	WO2005120643A8 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms
12/14/2006	WO2005075425A3 Substituted bisarylurea derivatives as kinase inhibitors
12/14/2006	WO2001022972A9 Immunostimulatory nucleic acids
12/14/2006	US20060282908 Identification of the genetic determinants of the polymorphic CYP3A5 expression
12/14/2006	US20060281902 Human signal peptide-containing proteins
12/14/2006	US20060281887 (Meth)acrylate copolymer for use as medical carrier
12/14/2006	US20060281804 N-Benzyl-2,3,4,9-tetrahydrocarbazole-1-amine hydrochloride salt, for the treatment of human papillomaviruses infection, genital warts, or cervical dysplasia
12/14/2006	US20060281798 Methods of using thiazolidinedithione derivatives
12/14/2006	US20060281789 Protein kinase inhibitors
12/14/2006	US20060281762 1,3-Benzoxazolyl derivatives as kinase inhibitors
12/14/2006	US20060281761 Osteoporosis; oral diseases; bone disorders; atherosclerosis; antiarthritic agents; autoimmune disease; cachexia
12/14/2006	US20060281736 Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent
12/14/2006	US20060281731 3,4,5-trihydroxy-2-methoxy-8,8-dimethyl-non-enoic acid ((3S,6S)-6-azido-2-oxo-azepan-3-yl)-amide; less toxicity, better selectivity in killing cancer cells, minimal effect on normal healthy cells
12/14/2006	US20060281719 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
12/14/2006	US20060281714 Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
12/14/2006	US20060281706 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral
12/14/2006	US20060281704 Regulation of endogenous gene expression in cells using zinc finger proteins
12/14/2006	US20060281685 biodrug as antitumor agents; hormone sensitive tumors; therapy for prostate gland or breast cancer
12/14/2006	US20060281679 Human FGF-23 gene and gene expression products
12/14/2006	US20060281674 Reducing the risk of infection in a patient with lowered neutrophil count byadministering an immunostimulant S100 protein; immunosuppressed, chemotherapy-treatedpatients and those having bone marrow transplant; measurement of neutrophil bloodconcentrations; side effect reduction; cost efficiency
12/14/2006	US20060281672 Dec-205 (ly 75)/dcl-1 intergenic splice variants associated with hodgkin's disease, and uses thereof
12/14/2006	US20060281666 Substitute thiophenes and uses therof
12/14/2006	US20060281152 Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
12/14/2006	US20060281149 Transforming growth factor-beta-related molecules and uses thereof
12/14/2006	US20060281146 Novel compositions and methods for the treatment of immune related diseases
12/14/2006	US20060281125 ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
12/14/2006	US20060281081 Method of diagnosing colon and gastric cancers
12/14/2006	US20060281072 Stimulation of human T-cells and used to enhance antigen-specific immune responses; immunotherapy
12/14/2006	US20060280820 Use of an extract of Aloysia/Verbena/Lippia triphylla/citriodora for the treatment of chronic and/or inflammatory diseases
12/14/2006	US20060280756 Novel composition
12/14/2006	US20060280749 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
12/14/2006	DE102005026081A1 Extraction of immunologically active polymers, comprises prepurifying and enzymatically releasing the active polymers from mushroom cell walls by different chitinase
12/14/2006	DE102005026051A1 Mixture, useful in photodynamic therapy as photosensitizer and/or fluorescence active substance, comprises chlorin e6 derivatives and pyrrolidone derivatives
12/14/2006	CA2614295A1 Transcription factor decoy
12/14/2006	CA2611450A1 Method for producing polymerized coordination compounds of platinum complex
12/14/2006	CA2611445A1 Method for evaluation of compound using rsk1
12/14/2006	CA2611401A1 Oxindoles as kinase inhibitors
12/14/2006	CA2611391A1 Angiogenesis inhibitors
12/14/2006	CA2611201A1 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
12/14/2006	CA2611200A1 Stabilised il-21 compositions
12/14/2006	CA2610977A1 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
12/14/2006	CA2610975A1 Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
12/14/2006	CA2610838A1 Novel salts of conjugated psychotropic drugs and processes of preparing same
12/14/2006	CA2610792A1 Synthesis of glycerolipid carbamates and dicarbamates and their use as antitumor compounds
12/14/2006	CA2610771A1 Anti-trkb monoclonal antibodies and uses thereof
12/14/2006	CA2610685A1 Methods of treating, diagnosing or detecting cancer using an ephb3 modulator
12/14/2006	CA2610396A1 Organic compounds
12/14/2006	CA2609208A1 Use of plant cell membrane for the treatment of obesity
12/14/2006	CA2608814A1 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
12/14/2006	CA2607337A1 Indole derivatives having antitumor activity
12/14/2006	CA2607184A1 Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumour agents
12/14/2006	CA2606293A1 Hdac regulation assays, compounds and therapeutic compositions
12/14/2006	CA2601202A1 New hybrid oligomers. their preparation process and pharmaceutical compositions containing them
12/13/2006	EP1731615A1 Cytoplasmic localization dna and rna
12/13/2006	EP1731609A1 Rad51 EXPRESSION INHIBITOR, DRUG CONTAINING THE INHIBITOR AS THE ACTIVE INGREDIENT AND UTILIZATION THEREOF
12/13/2006	EP1731605A1 Cancer antigen peptides derived from wt1
12/13/2006	EP1731599A1 Method of constructing recombinant herpes simplex virus
12/13/2006	EP1731531A2 Multiple cytokine-antibody complexes
12/13/2006	EP1731523A1 Thiazolopyrimidine derivative
12/13/2006	EP1731520A1 Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3
12/13/2006	EP1731519A1 Novel indole derivative for alkylating specific base sequence of dna and alkylating agent and drug each comprising the same
12/13/2006	EP1731511A1 BicyclischeI heterocycles, medicaments containing these compounds, their use and methods for the production thereof
12/13/2006	EP1731173A1 Complex particles and coated complex particles
12/13/2006	EP1731172A1 Liposome preparation
12/13/2006	EP1731168A1 Antibody drug
12/13/2006	EP1731165A1 Allogenic placenta-lysates/BCG-vaccine
12/13/2006	EP1731164A1 Methods for using the obese gene and its gene product to stimulate hematopoietic development
12/13/2006	EP1731162A2 Apparatus, method and compositions for the treatment of cancers by ultraphoresis
12/13/2006	EP1731161A1 Compositions for the treatment of diseases associated with elevated sphingolipid concentrations
12/13/2006	EP1731160A1 Cancer metastasis inhibitory composition
12/13/2006	EP1731157A2 Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol

1 ... 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 ... 2211